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Summary.-The effect has been studied of adding either misonidazole (MISO) or metronidazole (METRO) to cytotoxic drug treatment of C3H mice bearing the RIF-1 sarcoma. The nitroimidazoles were injected 30 min before the cytotoxic drugs at a dose of 2'5 mmol/kg. Both clonogenic-cell survival and growth delay were measured as indicators of tumour response and depression in WBC count and acute lethality were used to indicate normal-tissue response. For melphalan, neither pretreatment agent produced any change in tumour response. For cyclophosphamide, no change was produced by METRO but a minimal increase in tumour response occurred with MISO. An enhancement of cell killing by CCNU was seen with MISO pretreatment, but there was no increase in tumour growth delay. METRO, however, did not enhance tumour response by either endpoint. WBC depression by CCNU was not enhanced by MISO pretreatment, and there was no significant reduction in the acute LD50. This indicates a therapeutic advantage from the addition of MISO to CCNU in this model system. For chlorambucil, considerable enhancement of tumour response followed either MISO or METRO pretreatment (dose-modifying factors of 2.0 and 1*4 respectively). However, the modification by MISO of normaltissue response to chlorambucil was also enhanced by about a factor of 2, with no therapeutic gain. SEVERAL RECENT STUDIES have demonstrated that tumour response to cytotoxic drugs in mice can be enhanced by the 2-nitroimidazole misonidazole (MISO), a radiosensitizer of hypoxic cells (Rose et al., 1980; Clement et al., 1980; Tannock, 1980a, b; Siemann, 1981 Siemann, , 1982 Twentyman, 1981; Law et al., 1981; Mulcahy et al., 1981; Martin et al., 1981; Clutterbuck et al., 1982; Stephens et al., 1981) . In some of these studies (but not all) a therapeutic gain is claimed, in that enhancement of tumour response is greater than enhancement of normal-tissue damage.
Using the RIF-1 sarcoma in C3H mice, we have recently found that tumour growth delay induced by cyclophosphamide is considerably enhanced by the simultaneous administration of 5 mmol/ kg (1 mg/g) MISO. At lower doses of MISO, however, much of the effect is lost (Twentyman, 1981) .
In this paper, we describe experiments using the RIF-1 sarcoma in which we have studied the enhancement of a number of cytotoxic drugs by both MISO and the less electron-affinic 5-nitroimidazole analogue, metronidazole (METRO). The cytotoxic drugs studied were the nitrogen mustards, cyclophosphamide (CTX), melphalan (MEL) and chlorambucil (CHL), and the nitrosourea CCNU. Both growth delay and survival of clonogenic cells have been used as measures of tumour response. Depression of white blood cell (WBC) count and lethality have also been studied as indicators of normal-tissue response.
Mice and tumours.-The mice used in these studies were inbred C3H/He supplied by OLAC. Both male and female mice were used in different experiments, without any apparent differences in tumour growth rate or therapeutic response. Mice entered experiments at the age of 12-16 weeks and weighed 20-28 g.
Details of the RIF-1 mouse sarcoma have been previously described , as have the methods used for tumourcell inoculation into the gastrocnemius muscle of the hind limb, the subsequent measurement of tumour growth, and the conversion of leg measurements to tumour weight (Twentyman et al., 1979) . The endpoint of growth delay was calculated from the time taken for individual tumours to reach 4 x the initial group-mean treatment volume. In these experiments, tumours were 300-600 mg at the time of treatment and 9-12 mice were used in each treatment group.
Cell survival acssay.-Twenty-four hour-s after drug treatment, mice were killed and the RIF-1 tumours were excised from the hind legs. Pooled tumour material from 2 identically treated mice w%as used to assay cell survival at each treatment point. The tumours were weighed and minced finely with scissors. The resulting brei was then agitated for 45 min in a solution of 1 mg/ml of neutral protease (Type IX, Sigma Chemical Co.) (Twentyman & Yuhas, 1980) (Workman, unpublished) and also lies within the range of times found to be optimal for CTX in combination with 3-75 or 5 mmol/kg of MISO (Twentyman, 1981; Law et al., 1981) .
RESULTS

Melphalan
The effect of MISO or METRO pretreatment on cell survival after MEL is shown in Fig. 1 . The points for mice receiving sensitizers are scattered around the line drawn through the points for MEL alone; hence there is no evident enhancement of tumour response at MEL doses up to and beyond the acute LD50s1 25 mg/ kg. Similarly the growth delay (Table II) indicates little if any enhancement by MISO.
Cyclophosphamide
The cell-survival data for CTX are shown in Fig. 2 . The solid line is drawn by eye to fit the points for CTX alone. There is a tendency for the points for mice receiving MISO to be below the solid line, and this trend is indicated by the broken line. The effect is, however, small and not measured below 10-4 using these techniques. There is no effect with METRO.
Our previously published growth-delay data for CTX (Twentyman, 1981) 5-3 (1-2) 1-8 (0-6) 2-2 (0.9) 4-2 (0.9) 6-1 (1*1) 0-6 (1-6) 2-0 (1-6) 4-4 (1*6) 5-2 (1.0) 4-8 (3.2) 4*9 (1-5) 6*1 (2.5) 6 5 (3.4) 4-3 (1-6) 9-8 (0.4) 4-9(1.1) 9-9(1-4) 2.3 (1-3) 5-7 (1.1) Growth delayt (days) regeneration of surviving clonogenic cells persist to several times the treatment volume as has been previously reported in the B 16 melanoma (Stephens & Peacock, 1977 Fig. 6 ; they are combined data from 3 experiments. In 2 of the experiments a small depression in WBC count was caused by MISO alone. In the third experiment there was no such initial depression, but the curves clearly separated with increasing CHL dose up to 9 mg/kg. From the combined data a DMF of 2-2 is calculated from the ratio of CHL doses to halve the initial count with and without MISO pretreatment. There is a levelling-off of Error bars show +2 x s.e.
the counts at higher doses, presumably because of a CHL-resistant fraction of WBC.
DISCUSSION
In these experiments we have used a lower dose (2.5 mmol/kg) of MISO than than has been used in most of the previously reported studies of radiosensitizer/ cytotoxic drug combinations. In our mice, a MISO dose of 5 mmol/kg produces a drop in body temperature of 5-6°C, persisting for 10-12 h. We feel that such a profound effect on body temperature may well complicate the analysis of response to subsequently administered cytotoxic drugs by interfering with drug metabolism. At 2*5 mmol/kg, however, the drop in body temperature is not more than 1°C for less than 3 h, and any such problems will therefore be largely eliminated. It should also be pointed out that a dose of 2-5 mmol/kg still produces plasma levels of MISO which are many times higher than Tannock (1980b) . A DMF of 2-2 was obtained by combining 5 mmol/kg of MISO with CTX in the Lewis lung tumour (Rose et al., 1980) and more recently, Stephens et al. (1981) have reported DMFs of 2 0 and 2-6 for this same combination in the Lewis lung tumour and HX32 xenograft respectively. In our own previous study (Twentyman, 1981) and a similar study by Law et al. (1981) , both using the RIF-1 mouse tumour, a DMF of 2-0 was found for MISO (5 mmol/kg) in combination with low doses of CTX (below 60 mg/kg). At higher CTX doses, however, the DMF was greatly reduced. We also found that the effect in this tumour was much reduced at lower doses of MISO.
A relatively small DMF of , 1-4 for CTX with 5 mmol/kg MISO was, however, found in the KHT tumour by Dr D. W. Siemann (personal communication) and this agrees with our finding of only a small enhancement in this tumour (Twentyman, 1981) .
Clearly the enhancing effect of MISO on CTX is very variable. Although most tumours show an enhancement at a MISO dose of 5 mmol/kg, the effect may be lost with lower doses, and in the RIF-1 tumour is barely significant at 2-5 mmol/ kg.
CCNU
Interaction between CCNU and MISO has been extensively studied by Siemann (1981 Siemann ( , 1982 . He demonstrated that, in the KHT sarcoma, a DMF of 2.0 could be obtained with 5 mmol/kg of MISO, and that only a small reduction in the DMF was caused by reducing the MISO dose to 2-5 mmol/kg. Normal tissue toxicity of CCNU (assessed in an LD50 assay) was enhanced by DMFs of only 1P14 and 1-36 at 2-5 and 5 mmol/kg of MISO, however, and CCNU-induced depression of WBC count was enhanced by a factor of 1 1-1P4. There was, therefore, a clear therapeutic gain. In the RIF-1 tumour the DMF was 2.0 for 5 mmol/kg of MISO, and in the MT-1 mammary tumour the DMF was 1P5 at 2-5 mmol/kg of MISO (Siemann, 1982) . In the study by Stephens et al. (1981) a MISO dose of 3-75 mmol/kg enhanced the CCNU response of the Lewis lung tumour by a factor of 1P5. Our results presented in this paper indicate that there is a partial loss of enhancement in the RIF-1 tumour when the MISO dose is reduced from 5 to 2-5 mmol/kg. At higher CCNU doses, however, the enhancement is still significant, and the minimal increase in normal-tissue toxicity at this dose of MISO means that the combination is therapeutically advantageous in our system. Our findings of no enhancement of CCNU by METRO is in contrast to our result in the KHT sarcoma, where METRO at 2-5 mmol/kg produces a similar DMF to MISO at the same dose level (Workman & Twentyman, submitted) .
Chlorambucil
We are not aware of any other data for the combination of radiosensitizers with this agent. In this study, the DMFs for CHL in combination with MISO or METRO are larger than for any of the other agents (i.e., 2-0 and 1-4 respectively). We have obtained a similar factor for MISO and CHL in the KHT and EMT6 tumours (unpublished) . In contrast to almost all other results in the literature, however, the enhancement of CHL in terms of whole-body toxicity (i.e., LD50) is as great as the enhancement against the tumour. In these experiments mice dying from either CHL alone or from CHL + MISO did so within 24 h of drug administration. This is also true of mice dying from very large doses of MISO alone, and it is not therefore possible to separate out the 2 components of the lethal effect. It would appear, however, that when animals die so rapidly, the cause of death is not cytotoxicity by conventional alkylation mechanisms. In this respect, therefore, enhancement of CHL toxicity by MISO is different in nature to that seen for other alkylating agents. However, the depression of WBC count (measured at Day 3) by CHL is also enhanced by MISO to the same extent as whole-body lethality, and this endpoint presumably reflects the cytotoxicity of CHL to WBC precursors in the marrow. The fact that MISO pretreatment enhances these 2 different mechanisms of toxicity would perhaps suggest that enhancement takes place via a non-specific modification of CHL pharmacokinetics.
Summarizing, these results indicate that in the RIF-1 tumour little or no enhancement of tumour response is produced by adding MISO (2.5 mmol/kg) to MEL or CTX. Enhancement of CCNU is seen at higher drug doses and is greater in the tumour response than in normal-tissue toxicity. For CHL, large DMFs are obtained, but these are as large for normal tissues as they are for the RIF-1 tumour, so this combination produces no therapeutic gain.
METRO is clearly less active than equimolar MISO in combination with the cytotoxic drugs investigated here. We are currently involved in a detailed study of the effect of electron affinity and lipoDhilicity of nitroimidazoles on sensitization to various cytotoxic agents. Preliminary studies have revealed a number of analogues more active than MISO in combination with CCNU.
These data, taken together with data reported by others, confirm the very variable nature of drug enhancement by radiosensitizers. Mechanistic studies are urgently required to elucidate the nature of the interaction.
